Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections: Further favorable experience

J. F. Fisher, K. Woeltje, A. Espinel-Ingroff, J. Stanfield, J. T. DiPiro

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Studies in experimental animals and humans have shown that Amphotericin B (AmB) persists in urine for days to weeks after a single IV dose in levels that should inhibit candidal organisms and thereby obviate the need for frequent dosing. Including data from four previously described patients, we have now treated a total of 11 patients (12 episodes) with Candida urinary tract infections with single-dose AmB (six, Candida albicans; two, C. tropicalis; four, other nonalbicans Candida). The duration of candiduria prior to entry ranged from 18 to 180 days. Predisposing conditions included renal transplantation (1), diabetes mellitus (8), genitourinary stones (1) or anomalies (4), catheterization (2), and antibacterial therapy (11). A single patient was intolerant of AmB. Out of 11 evaluable candiduric episodes, eight resolved. Failure occurred in one patient with a chronic indwelling bladder catheter and in the allograft recipient. The data suggest that the sustained urinary excretion of AmB may permit successful single- or paucidose therapy of Candida urinary tract infections in some patients with a minimum of toxicity.

Original languageEnglish (US)
Pages (from-to)1024-1027
Number of pages4
JournalClinical Microbiology and Infection
Volume9
Issue number10
DOIs
StatePublished - Oct 2003

Fingerprint

Amphotericin B
Candida
Urinary Tract Infections
Indwelling Catheters
Candida albicans
Catheterization
Kidney Transplantation
Allografts
Diabetes Mellitus
Urinary Bladder
Urine
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections : Further favorable experience. / Fisher, J. F.; Woeltje, K.; Espinel-Ingroff, A.; Stanfield, J.; DiPiro, J. T.

In: Clinical Microbiology and Infection, Vol. 9, No. 10, 10.2003, p. 1024-1027.

Research output: Contribution to journalArticle

Fisher, J. F. ; Woeltje, K. ; Espinel-Ingroff, A. ; Stanfield, J. ; DiPiro, J. T. / Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections : Further favorable experience. In: Clinical Microbiology and Infection. 2003 ; Vol. 9, No. 10. pp. 1024-1027.
@article{8cd3701eb89942a3a5695c419329bbe1,
title = "Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections: Further favorable experience",
abstract = "Studies in experimental animals and humans have shown that Amphotericin B (AmB) persists in urine for days to weeks after a single IV dose in levels that should inhibit candidal organisms and thereby obviate the need for frequent dosing. Including data from four previously described patients, we have now treated a total of 11 patients (12 episodes) with Candida urinary tract infections with single-dose AmB (six, Candida albicans; two, C. tropicalis; four, other nonalbicans Candida). The duration of candiduria prior to entry ranged from 18 to 180 days. Predisposing conditions included renal transplantation (1), diabetes mellitus (8), genitourinary stones (1) or anomalies (4), catheterization (2), and antibacterial therapy (11). A single patient was intolerant of AmB. Out of 11 evaluable candiduric episodes, eight resolved. Failure occurred in one patient with a chronic indwelling bladder catheter and in the allograft recipient. The data suggest that the sustained urinary excretion of AmB may permit successful single- or paucidose therapy of Candida urinary tract infections in some patients with a minimum of toxicity.",
author = "Fisher, {J. F.} and K. Woeltje and A. Espinel-Ingroff and J. Stanfield and DiPiro, {J. T.}",
year = "2003",
month = "10",
doi = "10.1046/j.1469-0691.2003.00711.x",
language = "English (US)",
volume = "9",
pages = "1024--1027",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections

T2 - Further favorable experience

AU - Fisher, J. F.

AU - Woeltje, K.

AU - Espinel-Ingroff, A.

AU - Stanfield, J.

AU - DiPiro, J. T.

PY - 2003/10

Y1 - 2003/10

N2 - Studies in experimental animals and humans have shown that Amphotericin B (AmB) persists in urine for days to weeks after a single IV dose in levels that should inhibit candidal organisms and thereby obviate the need for frequent dosing. Including data from four previously described patients, we have now treated a total of 11 patients (12 episodes) with Candida urinary tract infections with single-dose AmB (six, Candida albicans; two, C. tropicalis; four, other nonalbicans Candida). The duration of candiduria prior to entry ranged from 18 to 180 days. Predisposing conditions included renal transplantation (1), diabetes mellitus (8), genitourinary stones (1) or anomalies (4), catheterization (2), and antibacterial therapy (11). A single patient was intolerant of AmB. Out of 11 evaluable candiduric episodes, eight resolved. Failure occurred in one patient with a chronic indwelling bladder catheter and in the allograft recipient. The data suggest that the sustained urinary excretion of AmB may permit successful single- or paucidose therapy of Candida urinary tract infections in some patients with a minimum of toxicity.

AB - Studies in experimental animals and humans have shown that Amphotericin B (AmB) persists in urine for days to weeks after a single IV dose in levels that should inhibit candidal organisms and thereby obviate the need for frequent dosing. Including data from four previously described patients, we have now treated a total of 11 patients (12 episodes) with Candida urinary tract infections with single-dose AmB (six, Candida albicans; two, C. tropicalis; four, other nonalbicans Candida). The duration of candiduria prior to entry ranged from 18 to 180 days. Predisposing conditions included renal transplantation (1), diabetes mellitus (8), genitourinary stones (1) or anomalies (4), catheterization (2), and antibacterial therapy (11). A single patient was intolerant of AmB. Out of 11 evaluable candiduric episodes, eight resolved. Failure occurred in one patient with a chronic indwelling bladder catheter and in the allograft recipient. The data suggest that the sustained urinary excretion of AmB may permit successful single- or paucidose therapy of Candida urinary tract infections in some patients with a minimum of toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0242268547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242268547&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2003.00711.x

DO - 10.1046/j.1469-0691.2003.00711.x

M3 - Article

C2 - 14616745

AN - SCOPUS:0242268547

VL - 9

SP - 1024

EP - 1027

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 10

ER -